Literature DB >> 19627485

Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status.

Nitin Saini1, Radhika Srinivasan, Yogesh Chawla, Sanjeev Sharma, Anuradha Chakraborti, Arvind Rajwanshi.   

Abstract

BACKGROUND: Telomerase expression and the maintenance of a critical telomere length (TL) in cancer initiation indicates that telomere shortening and telomerase expression initiates cancer by induction of chromosomal instability.
METHODS: Telomerase activity, TL and human telomerase reverse transcriptase (hTERT) expression were investigated in 58 hepatocellular carcinoma (HCC) and 17 chronic hepatitis patients by the telomerase repeat amplification protocol, Southern blotting and reverse transcriptase-polymerase chain reaction.
RESULTS: Telomerase was positive in 76% of HCC and 11.8% of chronic hepatitis patients (P<0.0001). The mean telomere length (MTL) in HCC was significantly shorter compared with chronic hepatitis (P<0.0001). The MTL was not significantly different in HCC patients with and without cirrhosis (P=0.77). In hepatitis B virus, hepatitis C virus and non-B non-C-related HCC groups, no differences were found in telomerase activity and MTL (P=0.77). hTERT, a regulator of telomerase, was, however, positive in 81% of HCCs. The correlation between telomerase activity and hTERT mRNA expression was statistically significant (P<0.0001). The MTL in telomerase-positive HCC cases was significantly shorter than the MTL in telomerase-negative cases (P<0.0001).
CONCLUSION: The majority of HCCs exhibited telomerase activity that correlated well with hTERT expression. MTL in HCC was significantly shorter than chronic hepatitis. It was also found that shorter telomeres are present in telomerase-positive HCC cases. However, no correlation was found between telomerase activity and TL with respect to the viral status in HCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19627485     DOI: 10.1111/j.1478-3231.2009.02082.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  20 in total

1.  Relative telomere length: a novel non-invasive biomarker for the risk of non-cirrhotic hepatocellular carcinoma in patients with chronic hepatitis B infection.

Authors:  Xiaoying Fu; Shaogui Wan; Hie-Won Hann; Ronald E Myers; Richard S Hann; Jennifer Au; Bicui Chen; Jinliang Xing; Hushan Yang
Journal:  Eur J Cancer       Date:  2012-03-21       Impact factor: 9.162

Review 2.  The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations.

Authors:  Ashish Kumar; Subrat K Acharya; Shivaram P Singh; Vivek A Saraswat; Anil Arora; Ajay Duseja; Mahesh K Goenka; Deepali Jain; Premashish Kar; Manoj Kumar; Vinay Kumaran; Kunisshery M Mohandas; Dipanjan Panda; Shashi B Paul; Jeyamani Ramachandran; Hariharan Ramesh; Padaki N Rao; Samir R Shah; Hanish Sharma; Ragesh B Thandassery
Journal:  J Clin Exp Hepatol       Date:  2014-05-22

Review 3.  Immunotherapy for hepatocellular carcinoma: From basic research to clinical use.

Authors:  Yu-Peng Hong; Zi-Duo Li; Pankaj Prasoon; Qi Zhang
Journal:  World J Hepatol       Date:  2015-05-08

4.  Potentiating cancer vaccine efficacy in liver cancer.

Authors:  Maria Tagliamonte; Annacarmen Petrizzo; Angela Mauriello; Maria Lina Tornesello; Franco M Buonaguro; Luigi Buonaguro
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

Review 5.  Latest developments in precancerous lesions of hepatocellular carcinoma.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Wen-Hong Wang; Jing Zhao
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

Review 6.  Effects of antiviral therapy on preventing liver tumorigenesis and hepatocellular carcinoma recurrence.

Authors:  Zhong-Ming Tan; Bei-Cheng Sun
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

7.  Cause-specific telomere factors deregulation in hepatocellular carcinoma.

Authors:  Manale El Idrissi; Valérie Hervieu; Philippe Merle; Franck Mortreux; Eric Wattel
Journal:  J Exp Clin Cancer Res       Date:  2013-09-11

8.  Effects of treatment with platinum azidothymidine and azidothymidine on telomerase activity and bcl-2 concentration in hepatocellular carcinoma- induced rats.

Authors:  Abdolreza Sabokrouh; Mohammad Taghi Goodarzi; Asad Vaisi-Raygani; Shohreh Khatami; Masoud Taghizadeh-Jahed
Journal:  Avicenna J Med Biotechnol       Date:  2014-10

9.  Oxidative DNA damage correlates with cell immortalization and mir-92 expression in hepatocellular carcinoma.

Authors:  Romilda Cardin; Cardin Romilda; Marika Piciocchi; Piciocchi Marika; Alessandro Sinigaglia; Sinigaglia Alessandro; Enrico Lavezzo; Lavezzo Enrico; Marina Bortolami; Bortolami Marina; Andromachi Kotsafti; Kotsafti Andromachi; Umberto Cillo; Cillo Umberto; Giacomo Zanus; Zanus Giacomo; Claudia Mescoli; Mescoli Claudia; Massimo Rugge; Rugge Massimo; Fabio Farinati; Farinati Fabio
Journal:  BMC Cancer       Date:  2012-05-15       Impact factor: 4.430

10.  The effect of hydroxycamptothecin and pingyangmycin on human squamous cell carcinoma of the tongue.

Authors:  Peng Chen; Bing Liu; Ming Hu
Journal:  Oncol Lett       Date:  2013-01-07       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.